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Introduction {#sec005}
============

Respiratory syncytial virus (RSV) is a leading cause of hospitalization and can result in serious morbidity and mortality in infants, particularly infants born preterm or with a high-risk medical condition such as chronic lung disease (CLD) or congenital heart disease (CHD) \[[@pone.0205399.ref001]--[@pone.0205399.ref004]\]. Because of the high burden of disease, interventions to prevent serious RSV disease have been implemented in the past 2 decades for these high-risk infants \[[@pone.0205399.ref005]--[@pone.0205399.ref007]\]. There have been reports of reduced incidence of RSV and/or bronchiolitis hospitalization in recent years for infants overall and specifically for infants with CLD and CHD \[[@pone.0205399.ref001], [@pone.0205399.ref008], [@pone.0205399.ref009]\]. However, none of these studies have employed a cohort design in which the population is prospectively followed forward in time; instead, they have used estimated denominator populations based on national birth statistics. Furthermore, due to this design limitation, no study has examined hospitalization rates among preterm infants because gestational age (GA) at birth was not available for hospitalized infants. It is not clear whether observations of reduced hospitalizations for RSV and bronchiolitis may be due to improvements and changes in the care of neonatal and infant respiratory disease in general, or whether prevention and intervention measures targeted directly at RSV have been particularly effective. Specifically, RSV immunoprophylaxis of high-risk infants with palivizumab was increasingly utilized in the United States during the study period following its licensure in 1998.

In this study, we assessed infant hospitalization trends for RSV and unspecified bronchiolitis (UB) by presence of higher-risk medical conditions and GA during the first year of life in a population-based cohort. We compared trends for those infants to those without higher-risk medical conditions. By using statewide California databases linked with patient identifiers, we tracked infants from birth through the first year of life and accounted for admissions to any hospital in the state.

Methods {#sec006}
=======

California hospital discharge data from the Office of Statewide Hospital Planning & Development (OSHPD) linked to vital statistics for 1997--2011 were used to create a longitudinal, population-based cohort of newborns followed to 1 year of age. These years were those for which complete data were available. The OSHPD database of hospital discharges captures almost all hospital births and subsequent hospital admissions in California, with the exception of military hospitals or birthing centers not reporting to OSHPD (\<3% of all deliveries). Although there is a separate record for each hospitalization, a unique identifier for each individual allows matching of patients across their first year after delivery. The probabilistic linkage algorithm used to perform the patient match by OSHPD is robust and described in detail previously \[[@pone.0205399.ref010]\]. In addition to various sociodemographic characteristics, each record contains a list of International Classification of Diseases-9 (ICD-9) codes to characterize the admission.

Birth hospitalizations were identified using ICD-9 codes V30.XX--V39.XX as in previous work and included delivery hospitalizations as well as subsequent transferred admissions \[[@pone.0205399.ref001]\]. California birth hospitalizations regardless of state of residence were included; the large majority (\>98%) were California residents. We included infants who had GA of 22--44 weeks recorded on their birth certificates. Individuals with potential errors in coding GA, death during delivery or during the birth hospitalization, or inconsistent data, such as admission occurring after the date of death, were excluded.

Infants were categorized according to medical condition as noted in [S1 Table](#pone.0205399.s001){ref-type="supplementary-material"}. Any diagnosis occurring at any time point during the first year of life was assigned as a characteristic of that infant. CHD diagnoses were characterized into high-risk or low-risk strata consistent with previous research \[[@pone.0205399.ref001]\], with high-risk superseding low-risk status. As a category for analysis, Down syndrome without CHD was considered separately and was mutually exclusive of higher-risk or lower-risk CHD. A category of "other high-risk" was created, encompassing cystic fibrosis with pulmonary manifestations, neuromuscular disease, human immunodeficiency virus, immunodeficiency, and congenital and metabolic disease. The other high-risk group excluded infants with CLD, high-risk or low-risk CHD, Down syndrome, and congenital anomalies of the respiratory system.

For the analyses of risk among infants by GA without other serious medical conditions, infants with CLD, congenital anomalies of the respiratory system, higher-risk CHD, or the other high-risk conditions were excluded. Down syndrome and lower-risk CHD were not excluded for this analysis, as these conditions have not traditionally been targeted for RSV-specific prevention efforts. A sensitivity analysis excluding lower-risk CHD and Down syndrome was performed to compare the results in infants without any comorbid conditions.

The outcomes of interest were hospital admission related to either RSV or UB occurring prior to 12 months of age. We identified transfers based on discharge from one hospital and admission to another hospital on the same date; transfers were classified as a single hospital admission. Patients with any relevant ICD-9 codes during the hospitalization for RSV (480.1, 466.11, 079.6) or UB (466.19, 466.1) listed as a diagnostic code were identified, with those having both considered as having RSV.

Annual trends of RSV- and UB-coded nonbirth hospital admissions during the first year after birth were compared by medical condition and then for those without medical conditions by GA category (22--28, 29--31, 32--34, 35--37, and 38--44 completed weeks GA). When presenting results for trends over time with years as the unit, the birth year of the patient was the basis for categorization. For example, if a nonbirth hospitalization for an infant born in November 2011 occurred in January 2012, this would be categorized as a 2011 patient and hospitalization. Infants were followed for 12 months or until death if this occurred within the first year of life. During follow-up, all hospitalizations, including repeat hospitalizations, were considered to be the event. Hospitalization rates were estimated per 100 person-years and were assessed for trends over time using unadjusted Poisson regression. By evaluating person-time incidence, we were able to adjust the exposure denominator for infants who died and were no longer eligible to be hospitalized, as well as adjust the numerator for infants who may have been hospitalized more than once for RSV or UB.

Analyses were conducted using SAS 9.4 software (SAS Institute, Cary, NC). This study was approved by the Stanford University Institutional Review Board. The patient data used in this study were fully anonymized prior to our access, and the Institutional Review Board waived the requirement for informed consent.

Results {#sec007}
=======

After exclusions, 7,298,401 infants were born and discharged to their homes after the birth hospitalization during the study period ([Fig 1](#pone.0205399.g001){ref-type="fig"}). In this cohort, 121,230 infants (1.7%) had an identified medical condition ([Table 1](#pone.0205399.t001){ref-type="table"}). In this cohort of infants with medical conditions, 95,785 nonbirth hospitalizations occurred during the first year of life; there were 6853 (7.2%) hospitalizations for RSV and 6568 (6.9%) for UB. The proportion of infants hospitalized for RSV and UB were 5.4% (6580 infants) and 4.9% (5915 infants), respectively in this cohort. Among infants without identified medical conditions, 712,135 nonbirth hospitalizations occurred: 96,694 (13.6%) for RSV and 69,886 (9.8%) for UB. The proportion of infants hospitalized was 1.3% (95,270 infants) for RSV and 0.9% (66,891 infants) for UB. Although RSV and UB were more common reasons for hospitalization in the cohort without medical conditions, hospitalization rates were higher for infants with medical conditions (5.9 per 100 person-years for both RSV and UB) compared with those without (1.3 and 1.0 per 100 person-years for RSV and UB, respectively). All-cause infant hospitalization declined by 24%, from 12.2 per 100 person-years in 1998 to 9.3 per 100 person-years in 2011 (ptrend \<0.001).

![Patient cohort.](pone.0205399.g001){#pone.0205399.g001}

10.1371/journal.pone.0205399.t001

###### Nonbirth hospitalizations by medical condition.

![](pone.0205399.t001){#pone.0205399.t001g}

  Medical Condition                                                                        Number of Infants   Number of Hospitalizations During the First Year   Number of RSV Hospitalizations During the First Year   Number of UB Hospitalizations
  ---------------------------------------------------------------------------------------- ------------------- -------------------------------------------------- ------------------------------------------------------ -------------------------------
  Infants with identified medical conditions                                                                                                                                                                             
  Chronic respiratory disease arising in the perinatal period (ie, chronic lung disease)   19,347              13,905                                             1316                                                   1651
  Congenital anomalies of the respiratory system                                           18,900              20,076                                             1207                                                   1646
  Higher-risk congenital heart disease                                                     63,893              49,775                                             3760                                                   3134
  Lower-risk congenital heart disease                                                      91,944              30,547                                             3324                                                   2987
  Down syndrome without congenital heart disease                                           4463                2220                                               293                                                    276
  Cystic fibrosis with pulmonary manifestations                                            845                 1142                                               73                                                     71
  Neuromuscular disease                                                                    2553                4568                                               261                                                    269
  Human immunodeficiency virus                                                             3                   3                                                  0                                                      0
  Immunodeficiency                                                                         1923                3372                                               204                                                    208
  Congenital and metabolic                                                                 32,325              29,862                                             1519                                                   1500
  Infants without serious medical conditions by GA                                                                                                                                                                       
  22--28 weeks                                                                             24,963              3607                                               546                                                    478
  29--31 weeks                                                                             52,690              6637                                               1076                                                   920
  32--34 weeks                                                                             194,821             21,829                                             3733                                                   2558
  35--37 weeks                                                                             1,062,530           112,944                                            16,787                                                 11,693
  ≥38 weeks                                                                                5,842,167           487,074                                            73,128                                                 51,242

GA, gestational age; RSV, respiratory syncytial virus; UB, unspecified bronchiolitis.

For infants without identified medical conditions, the rate of RSV hospitalization ranged from 0.8 to 1.8 hospitalizations per 100 person-years across birth year cohorts ([Fig 2A](#pone.0205399.g002){ref-type="fig"}). The rate was 1.4 hospitalizations per 100 person-years in 1998, 1.6 per 100 person-years in 2010, and 0.8 hospitalizations per 100 person-years in 2011 (ptrend \<0.001). The rate of UB hospitalization was less variable, with annual rates ranging from 0.8 to 1.1 hospitalizations per 100 person-years across the study period (ptrend \<0.001). For infants with identified medical conditions, RSV hospitalizations decreased across the study period, from 7.6 per 100 person-years in 1998 to 3.4 per 100 person-years in 2011 ([Fig 2A](#pone.0205399.g002){ref-type="fig"}) (ptrend \<0.001).

![Rates by identified medical condition.\
(A) Rates of RSV and UB by identified medical condition status. (B) Rates of RSV by identified medical condition. (C) Rates of UB by identified medical condition. CHD, congenital heart disease; CLD, chronic lung disease; RSV, respiratory syncytial virus; UB, unspecified bronchiolitis.](pone.0205399.g002){#pone.0205399.g002}

RSV hospitalizations decreased significantly for all high-risk conditions ([Fig 2B](#pone.0205399.g002){ref-type="fig"}). The largest relative drop occurred in infants with CLD (from 12.0 to 5.0 per 100 person-years; ptrend \<0.001) and high-risk CHD (7.6 to 3.2 per 100 person-years; ptrend \<0.001). Decreased rates were also seen for infants with congenital airway anomalies (9.1 to 4.3 per 100 person-years; ptrend \<0.001), low-risk CHD (4.9 to 2.2 per 100 person-years; ptrend = 0.001), Down syndrome without CHD (6.2 to 3.2 per 100 person-years; ptrend = 0.026), and other high-risk conditions (5.3 to 3.0 per 100 person-years; ptrend \<0.001).

To assess changes associated with years in which RSV immunoprophylaxis was increasingly used among high-risk populations \[[@pone.0205399.ref011], [@pone.0205399.ref012]\], trend tests were performed separately for 1998--2004 and 2005--2011. RSV hospitalization rates for infants with CLD decreased during 1998--2004 (ptrend \<0.001); however, the hospitalization rate did not decrease significantly after 2005. The RSV hospitalization rate for congenital airway anomalies declined over time (ptrend \<0.001), although the decreasing trends during 1998--2004 and 2005--2011 were not statistically significant during each time period. The trend of RSV hospitalization rates for high-risk CHD was examined from 1998--2002 and 2003--2011, as RSV immunoprophylaxis was first approved for this population in 2003. Although the rates of high-risk CHD were not significantly different between 1998 and 2002 (ptrend = 0.6347), rates did decrease significantly after 2003 (ptrend \<0.001). The rates of UB hospitalizations among infants with identified medical conditions showed less change ([Fig 2C](#pone.0205399.g002){ref-type="fig"}).

For infants without medical conditions, rates of RSV hospitalizations were highest for the most preterm infants and decreased with increasing GA ([Fig 3A](#pone.0205399.g003){ref-type="fig"}). RSV hospitalization rates decreased for all preterm GA categories, with greater decreases in those with earlier GA: 22--28 weeks (from 2.9 to 1.3 per 100 person-years), 29--31 weeks (from 3.0 to 1.4 per 100 person-years), 32--34 weeks (from 2.2 to 1.2 per 100 person-years), 35--37 weeks (from 1.6 to 1.0 per 100 person-years), and 38--44 weeks (from 1.3 to 0.8 per 100 person-years). Given the relative population sizes, the largest number of hospitalizations occurred in the 38--44 weeks GA group (n = 74,176) compared with all other GA groups combined (n = 22,518). The sensitivity analysis excluding all comorbid conditions showed similar results.

![Rates of hospitalization by GA in infants without medical conditions.\
(A) Rates of RSV by GA in infants without a medical condition. (B) Rates of UB by GA in infants without medical a condition. GA, gestational age; RSV, respiratory syncytial virus; UB, unspecified bronchiolitis.](pone.0205399.g003){#pone.0205399.g003}

Rates of UB remained more stable across GA groups ([Fig 3B](#pone.0205399.g003){ref-type="fig"}). A similar pattern of decreased risk by older GA was seen for UB hospitalizations. The total number of UB hospitalizations was 53,475 for infants 38--44 weeks GA and 16,411 for infants 22--37 weeks GA. RSV represented a lower proportion of all bronchiolitis (RSV or UB) hospitalizations among more preterm infants.

RSV and UB hospitalizations by sociodemographic and clinical characteristics are shown in [Table 2](#pone.0205399.t002){ref-type="table"}. Privately insured patients were less likely to be hospitalized in general, but particularly so for RSV and UB. This was true for infants with and without identified medical conditions.

10.1371/journal.pone.0205399.t002

###### Risk for RSV and UB hospitalization by high-risk and low-risk status.

![](pone.0205399.t002){#pone.0205399.t002g}

                                                            High Risk for RSV   Non--High Risk for RSV                                                                                                            
  ------------------------- ------------------------------- ------------------- ------------------------ -------- ------ ------ ------ ------ ------ ----------- ------ --------- ------ -------- ------ -------- ------
  Gestational age, wk       22--28                          13,945              11.5                     4338     7.2    519    7.9    685    11.6   24,963      0.3    3607      0.6    546      0.6    478      0.7
                            29--31                          7257                6.0                      2210     3.7    317    4.8    329    5.6    52,690      0.7    6637      1.1    1076     1.1    920      1.4
                            32--34                          9017                7.4                      3421     5.7    466    7.1    403    6.8    194,821     2.7    21,829    3.5    3733     3.9    2558     3.8
                            35--37                          20,413              16.8                     10,580   17.6   1179   17.9   971    16.4   1,062,530   14.8   112,944   17.9   16,787   17.6   11,693   17.5
                            38--44                          70,598              58.2                     39,396   65.7   4099   62.3   3527   59.6   5,842,167   81.4   487,074   77.1   73,128   76.8   51,242   76.6
  Birth weight, g           \<750                           5305                4.4                      1754     2.9    196    3.0    265    4.5    2830        0.0    519       0.1    44       0.0    62       0.1
                            750--999                        6706                5.5                      2010     3.4    249    3.8    311    5.3    7205        0.1    1312      0.2    162      0.2    198      0.3
                            1000--1249                      5237                4.3                      1582     2.6    225    3.4    263    4.4    12,778      0.2    1940      0.3    288      0.3    288      0.4
                            1250--1499                      3622                3.0                      1061     1.8    151    2.3    159    2.7    19,912      0.3    2643      0.4    426      0.4    352      0.5
                            1500--2499                      17,368              14.3                     7220     12.0   888    13.5   759    12.8   373,382     5.2    40,521    6.4    6787     7.1    4616     6.9
                            ≥2500                           82,991              68.5                     46,318   77.3   4871   74.0   4158   70.3   6,761,051   94.2   585,155   92.6   87,563   91.9   61,375   91.8
  Sex                       Female                          56,816              46.9                     26,607   44.4   2839   43.2   2317   39.2   3,506,807   48.9   269,675   42.7   40,486   42.5   26,103   39.0
                            Male                            64,407              53.1                     33,333   55.6   3740   56.8   3598   60.8   3,670,350   51.1   362,414   57.3   54,784   57.5   40,788   61.0
  Multiple gestation        Singleton                       110,999             91.6                     56,612   94.4   6204   94.3   5567   94.1   6,971,972   97.1   614,764   97.3   92,170   96.7   64,784   96.9
                            Multiple                        10,231              8.4                      3333     5.6    376    5.7    348    5.9    205,197     2.9    17,327    2.7    3100     3.3    2107     3.1
  Maternal age, y           \<20                            11,539              9.5                      5997     10.0   749    11.4   694    11.7   688,641     9.6    73,439    11.6   12,043   12.6   8563     12.8
                            20--24                          25,552              21.1                     13,253   22.1   1672   25.4   1452   24.5   1,588,727   22.1   156,782   24.8   25,264   26.5   18,221   27.2
                            25--29                          29,759              24.5                     15,032   25.1   1671   25.4   1498   25.3   1,899,977   26.5   166,052   26.3   25,175   26.4   17,842   26.7
                            30--34                          29,250              24.1                     14,298   23.9   1431   21.7   1271   21.5   1,771,955   24.7   141,320   22.4   19,939   20.9   13,615   20.4
                            35--39                          18,689              15.4                     8538     14.2   779    11.8   745    12.6   981,925     13.7   75,607    12.0   10,300   10.8   6932     10.4
                            40+                             6436                5.3                      2824     4.7    278    4.2    255    4.3    245,731     3.4    18,867    3.0    2545     2.7    1713     2.6
  Nulliparity               Multiparity                     73,852              60.9                     37,599   62.7   4595   69.9   4025   68.1   4,369,555   60.9   396,376   62.7   66,100   69.4   46,168   69.0
                            Nulliparity                     47,331              39.1                     22,326   37.3   1982   30.1   1888   31.9   2,805,715   39.1   235,548   37.3   29,140   30.6   20,703   31.0
  Maternal race             Non-Latina White                33,204              28.7                     15,518   27.1   1321   21.1   1182   20.7   1,985,227   28.9   147,085   24.3   21,505   23.6   12,339   19.1
                            Non-Latina Black                8793                7.6                      4184     7.3    480    7.7    470    8.2    383,794     5.6    36,622    6.0    5487     6.0    3899     6.0
                            Non-Latina Asian                11,614              10.0                     5591     9.8    431    6.9    431    7.6    798,010     11.6   59,355    9.8    6420     7.0    4325     6.7
                            Non-Latina Pacific Islander     631                 0.5                      313      0.5    29     0.5    45     0.8    34,878      0.5    3631      0.6    570      0.6    466      0.7
                            Latina                          61,066              52.7                     31,460   54.9   3975   63.5   3547   62.3   3,625,894   52.9   356,014   58.8   56,781   62.2   43,318   67.0
                            Non-Latina AIAN                 484                 0.4                      226      0.4    26     0.4    19     0.3    28,259      0.4    2686      0.4    441      0.5    299      0.5
                            Non-Latina Other                70                  0.1                      34       0.1    4076   62.1   3      0.1    3771        0.1    310       0.1    38       0.0    31       0.0
  Delivery payer            Medi-Cal                        58,439              48.3                     30,719   51.3   2298   35.0   3637   61.6   3,209,534   44.8   342,486   54.3   56,440   59.4   42,571   63.7
                            Private                         58,089              48.0                     27,173   45.4   112    1.7    2053   34.8   3,673,591   51.3   268,389   42.5   35,652   37.5   22,090   33.1
                            Self-pay/no charge/unattached   2339                1.9                      1000     1.7    82     1.2    109    1.8    155,906     2.2    9774      1.5    1501     1.6    1005     1.5
                            Other                           2081                1.7                      936      1.6    60     0.9    103    1.7    125,170     1.7    10,376    1.6    1491     1.6    1122     1.7
  Prenatal care visits, n   0                               1014                0.9                      380      0.6    1581   24.7   44     0.8    31,126      0.4    2839      0.5    537      0.6    387      0.6
                            1--9                            28,960              24.4                     12,691   21.6   4421   69.1   1522   26.4   1,216,103   17.3   114,141   18.5   18,091   19.4   12,600   19.4
                            10--19                          81,447              68.6                     42,175   71.9   340    5.3    3928   68.1   5,509,151   78.2   474,126   76.7   70,421   75.7   49,463   76.0
                            20+                             7263                6.1                      3385     5.8    \-     0.0    274    4.8    289,797     4.1    26,830    4.3    4022     4.3    2650     4.1

AIAN, American Indian and Alaska Native; g, grams; n, number; RSV, respiratory syncytial virus; UB, unspecified bronchiolitis; wk, weeks; y, years.

Discussion {#sec008}
==========

We evaluated trends in admissions for RSV and other bronchiolitis for neonates born in California, stratified by risk status. RSV and UB hospitalizations are common in the first year of life. Consistent with previous reports, RSV-coded hospitalizations have declined over the past decade. This was true for the general population of infants, and the greatest declines were observed for infants with CLD, high-risk CHD, and early preterm birth. On the other hand, admissions for RSV in term infants without medical conditions and for UB across all infant groups remained relatively stable from 1998 to 2011.

Various interventions, including RSV immunoprophylaxis, may have contributed to the observed declines in RSV hospitalizations. In a study of patients with significant heart disease using a US national sample of pediatric hospital admissions, a 36% decrease in RSV hospitalizations was seen when comparing pre- and post-palivizumab guidelines for that population \[[@pone.0205399.ref009]\]. A similar finding was observed for high-risk CHD and CLD in a second study \[[@pone.0205399.ref001]\]. Although we did not have patient-level data on RSV immunoprophylaxis, other studies have demonstrated trends of increasing palivizumab use between 1998 and the 2004--2006 timeframe \[[@pone.0205399.ref011], [@pone.0205399.ref012]\]. These trends correspond to the temporal trend of declining RSV admissions from 1998 to 2006 seen in our results for infants with medical conditions and early gestational age. We speculate that infants with other high-risk conditions that have not been explicitly targeted for immunoprophylaxis may also have had increased usage of palivizumab due to recognition of their high-risk medical status for respiratory illness. Continuing to target high-risk groups with optimal treatment strategies and implementation of quality improvement should lead to sustained public health benefit.

Breastfeeding is considered a public health benefit in part due to its potential for decreasing infections in infancy \[[@pone.0205399.ref013]\]. National trends in breastfeeding increased after 1999 and extend beyond the end of our study period \[[@pone.0205399.ref014], [@pone.0205399.ref015]\]. Increases in breastfeeding may have contributed to declines in RSV hospitalizations during the study period. Presumably the increase in breastfeeding and the protection against infection that it confers would have been reflected in the number of UB hospitalizations; however, the decline was not as pronounced during the study period. Furthermore, one study indicated a significantly lower rate of exclusive breastfeeding in preterm infants (8% vs 19%) \[[@pone.0205399.ref016]\], and high-risk infants may be less likely to sustain breastfeeding due to their medical complexity.

We found that infants who were covered by Medicaid had higher rates of RSV and UB hospitalization ([Table 2](#pone.0205399.t002){ref-type="table"}), a finding consistent with other studies \[[@pone.0205399.ref003]\]. These findings help validate this study's analytic approach of using linked California datasets to evaluate infant hospitalization rates.

Although this and previous studies have shown declines in all infant RSV and UB hospitalizations between 1998 and 2012, the magnitude of the declines have differed across studies \[[@pone.0205399.ref001], [@pone.0205399.ref008]\]. In the current study, RSV and UB hospitalizations declined by approximately 38% and 25%, respectively, among infants without medical conditions, in the context of a 25% decline in infant hospitalizations due to any cause. Doucette et al found that RSV and UB hospitalizations decreased by 10% and 34%, respectively, among infants without medical conditions between 1997 and 2012, in the context of a 25% decline in all-cause infant hospitalizations \[[@pone.0205399.ref001]\]. Hasegawa et al demonstrated a 21% reduction in infant bronchiolitis hospitalizations due to RSV and other causes between 2000 and 2009 \[[@pone.0205399.ref008]\]. The larger decline in RSV hospitalizations in the current study may be due to decreased testing for RSV during the study interval in California relative to other parts of the country, perhaps due to an increased prevalence of managed care and adoption of recommendations against routine testing for RSV, which would in turn lead to a decrease in RSV-coded respiratory illnesses \[[@pone.0205399.ref017]\].

Although there was a general decline in RSV hospitalizations during the study period, there was a sudden spike in RSV hospitalization rates in 2010 for most groups (Figs [2C](#pone.0205399.g002){ref-type="fig"} and [3A](#pone.0205399.g003){ref-type="fig"}), with a spike also seen among infants born in 2009 at \<28 weeks GA. However, by 2011, hospitalization rates were again consistent with the general trajectory observed in previous years. It is unclear why this spike in 2010 occurred. One speculation is that this was due to the timing of the 2009--2010 influenza pandemic, which likely inhibited RSV circulation and increased concern and confirmatory testing for viral respiratory disease, leading to increased incidence and diagnosis of RSV hospitalizations among at-risk groups the following RSV season. Additional factors such as seasonal differences in RSV strain pathogenicity could have also played a role. As additional years' data become available, it will be important to evaluate if 2010 is an anomaly or part of a trend of increasing annual variability. If the spike was due to increased testing during the 2009--2010 pandemic, the disease rates in 2010 can provide some insight into what RSV and UB hospitalization rates might be if there was more comprehensive laboratory testing for RSV.

A limitation of this study that should be considered is that this was an analysis of California hospitalizations of infants born in the state, and admissions could not be captured when infants moved out of state or had hospitalizations outside of California. It should also be noted that given the sample size, even small differences were expected to be statistically significant; as a result, the primary presentation of the results focuses on clinically meaningful differences rather than on statistical significance.

In summary, we found a general decline in RSV hospitalizations across a large population-based cohort. This was particularly true for high-risk conditions that are recommended for RSV immunoprophylaxis, such as CLD, high-risk CHD, and preterm birth at early GA. During this study period, the level of hospitalizations for UB remained relatively stable. As there appear to be interventions and preventive efforts that may alter outcomes, it will be important to continue research into which populations will benefit from targeted interventions and implement appropriate measures to provide maximal public health benefit.
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